2008 | 2007 | 2006 | 2005 | 2004 | 2003
|
| December 22, 2005 |
 Vasogen Files Shelf Prospectus |
 |
| December 15, 2005 |
| Vasogen Announces Senior Management Appointments |
|
| December 8, 2005 |
Vasogen to Present at Adams Harkness' Inflammatory Disease Company
Showcase & Panel Discussion on December 14, 2005 |
|
| December 7, 2005 |
| Vasogen Provides Update on Phase III Programs |
|
| November 21, 2005 |
| Dr. Eldon R. Smith, Vasogen’s VP Scientific Affairs, Appointed to the Order of Canada |
|
| November 17, 2005 |
| Vasogen’s VP025 Prevents Detrimental Effects of Beta-amyloid Exposure in Experimental Model of Alzheimer’s |
|
| November 16, 2005 |
| Vasogen’s VP025 Shown to Impact Inflammation-Signaling Pathways |
|
| November 14, 2005 |
| Vasogen’s ACCLAIM Trial in Advanced Chronic Heart Failure Reaches Target Number of Endpoint Events |
|
| November 3, 2005 |
| Vasogen Announces the Appointment of Terry Gregg as Vice Chairman |
|
| November 2, 2005 |
| Vasogen To Present at SG Cowen 6th Annual Global Health Care Conference |
|
| October 12, 2005 |
| Vasogen Announces Third Quarter 2005 Results |
|
| October 7, 2005 |
| Vasogen Announces Private Placement of US$40 Million of Senior Convertible Notes |
|
| October 5, 2005 |
| Vasogen to Conduct Quarterly Conference Call |
|
| September 21, 2005 |
| Update on Vasogen’s ACCLAIM Trial Presented Today at the Heart Failure Society of America Meeting |
|
| September 20, 2005 |
| Vasogen To Present at UBS Global Life Sciences Conference |
|
| August 30, 2005 |
| Vasogen Announces the Early Close Out of the SIMPADICO Peripheral Arterial Disease Trial |
|
| July 27, 2005 |
| Vasogen To Present at Adams Harkness' 25th Annual Summer Seminar |
|
| July 13, 2005 |
| Vasogen Announces Second Quarter 2005 Results |
|
| July 6, 2005 |
| Vasogen to Conduct Quarterly Conference Call |
|
| July 5, 2005 |
| Vasogen Announces Successful Results from Phase I Clinical Trial of VP025 |
|
| June 1, 2005 |
| Vasogen To Present at Pacific Growth Equities Life Sciences Conference |
|
| May 19, 2005 |
| Vasogen To Present at Needham & Company Biotechnology Conference |
|
| May 5, 2005 |
| Vasogen Reaches Full Enrollment in 2,000-Patient Pivotal Phase III ACCLAIM Trial in Advanced Chronic Heart Failure |
|
| April 13, 2005 |
| Vasogen Announces First Quarter 2005 Results |
|
| April 7, 2005 |
| Vasogen to Conduct Quarterly Conference Call |
|
| March 29, 2005 |
| Vasogen Preclinical Research Published in the Journal of Biological Chemistry |
|
| March 15, 2005 |
| Vasogen Granted European Patent in Chronic Heart Failure |
|
| March 14, 2005 |
| Vasogen to Conduct Video Webcast and Conference Call of Annual and Special Meeting |
|
| March 10, 2005 |
| Vasogen to Present at SG Cowen 25th Annual Health Care Conference |
|
| February 17, 2005 |
| Vasogen To Participate in Focus Session at BIO CEO & Investor Conference |
|
| February 3, 2005 |
| Vasogen Initiates Phase I Clinical Trial of VP025 |
|
| February 2, 2005 |
| Vasogen Completes US$42.3 Million Registered Direct Offering of Common Shares |
|
| January 28, 2005 |
| Vasogen Announces US$42.3 Million Registered Direct Offering of Common Shares |
|
| January 24, 2005 |
| Vasogen Receives Approval to Advance New Drug for Neuro-inflammatory Disease into Phase I Clinical Development |
|
| January 18, 2005 |
| Vasogen Announces 2004 Year-end Results |
|
| January 13, 2005 |
| Vasogen to Conduct Year-end Conference Call |
|
| January 5, 2005 |
| Vasogen Further Strengthens its Management Team |
|
Home 
Contact Us 
Search 
Site Map 
Printable Page